Core Viewpoint - Cosmos Health Inc. has entered into a manufacturing and supply agreement with Libytec Pharmaceutical S.A. for the production of the pharmaceutical product PathMuscle, enhancing its operational capabilities and revenue visibility in the European market [1][6][7]. Group 1: Agreement Details - The agreement entails Cosmos Health being responsible for the complete manufacturing process of PathMuscle, including formulation, production, quality control, and product release, adhering to regulatory requirements [2]. - The product PathMuscle is a fixed-dose combination of thiocolchicoside and paracetamol, aimed at treating musculoskeletal conditions by providing muscle relaxation and pain relief [3]. - PathMuscle is available in multiple oral presentations, including film-coated tablets and soluble tablets, and is indicated for the treatment of painful muscle spasms associated with acute musculoskeletal disorders [4]. Group 2: Production Volumes - The agreement specifies minimum committed production volumes of 591,500 units, with cumulative production volumes over five years expected to exceed 1.2 million units, depending on market demand [5]. Group 3: Strategic Implications - This agreement reflects Cosmos Health's vertically integrated manufacturing capabilities and is anticipated to improve capacity utilization and enhance revenue visibility across its operations [6]. - The CEO of Cosmos Health emphasized that this collaboration supports the company's strategic focus on expanding pharmaceutical manufacturing through long-term partnerships, showcasing its operational strength and regulatory expertise [7]. Group 4: Company Overview - Cosmos Health Inc. is a diversified global healthcare group, incorporated in 2009, with a portfolio of proprietary pharmaceutical and nutraceutical brands, and operates under European Good Manufacturing Practices [8]. - The company is involved in manufacturing pharmaceuticals, food supplements, and medical devices, and has established R&D partnerships targeting major health disorders, while also expanding its distribution network across Europe, Asia, and North America [8].